Zhou L, Cryan EV, D'Andrea MR, Belkowski S, Conway BR, Demarest KT. Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem. 2003;90:339–46. https://doi.org/10.1002/jcb.10631.

Article  CAS  PubMed  Google Scholar 

Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res. 2009;84:111–8. https://doi.org/10.1093/cvr/cvp190.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanwal A, Nizami HL, Mallapudi S, Putcha UK, Mohan GK, Banerjee SK. Inhibition of SGLT1 abrogates preconditioning-induced cardioprotection against ischemia-reperfusion injury. Biochem Biophys Res Commun. 2016;472:392–8. https://doi.org/10.1016/j.bbrc.2016.02.016.

Article  CAS  PubMed  Google Scholar 

Lee SY, Lee TW, Park GT, Kim JH, Lee HC, Han JH, Yoon A, Yoon D, Kim S, Jung SM, et al. Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction. Korean Circ J. 2021;51:251–62. https://doi.org/10.4070/kcj.2020.0303.

Article  CAS  PubMed  Google Scholar 

Kim DJ, Sheu WH, Chung WJ, Yabe D, Ha KH, Nangaku M, Tan EC, Node K, Yasui A, Lei W, et al. Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study. J Diabetes Investig. 2023;14:417–28. https://doi.org/10.1111/jdi.13959.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nikolaou PE, Mylonas N, Makridakis M, Makrecka-Kuka M, Iliou A, Zerikiotis S, Efentakis P, Kampoukos S, Kostomitsopoulos N, Vilskersts R, et al. Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect? Basic Res Cardiol. 2022;117:27. https://doi.org/10.1007/s00395-022-00934-7.

Article  CAS  PubMed  Google Scholar 

Azam MA, Chakraborty P, Si D, Du B, Masse S, Lai PFH, Ha ACT, Nanthakumar K. Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia. Life Sci. 2021;276:119440. https://doi.org/10.1016/j.lfs.2021.119440.

Article  CAS  PubMed  Google Scholar 

Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jorgensen ME, Thuresson M, et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136:249–59. https://doi.org/10.1161/CIRCULATIONAHA.117.029190.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang K, Xu Y, Wang D, Chen F, Tu Z, Qian J, Xu S, Xu Y, Hwa J, Li J, et al. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell. 2022;13:336–59. https://doi.org/10.1007/s13238-020-00809-4.

Article  CAS  PubMed  Google Scholar 

von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, Alber H, Berger R, Lichtenauer M, Saely CH, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43:4421–32. https://doi.org/10.1093/eurheartj/ehac494.

Article  CAS  Google Scholar 

Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, et al. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation. 2019;139:2516–27. https://doi.org/10.1161/CIRCULATIONAHA.119.039996.

Article  CAS  PubMed  Google Scholar 

Dayem KA, Younis O, Zarif B, Attia S, AbdelSalam A. Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients - DACAMI (a randomized controlled clinical trial). Int J Cardiol. 2023;379:9–14. https://doi.org/10.1016/j.ijcard.2023.03.002.

Article  PubMed  Google Scholar 

Marfella R, Sardu C, D'Onofrio N, Fumagalli C, Scisciola L, Sasso FC, Siniscalchi M, Marfella LV, D'Andrea D, Minicucci F, et al. SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes. BMC Med. 2023;21:71. https://doi.org/10.1186/s12916-023-02781-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gonzalez Perez A, Vizcaya D, Saez ME, Lind M, Garcia Rodriguez LA. Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK. BMJ Open Diabetes Res Care. 2023;11 https://doi.org/10.1136/bmjdrc-2022-003072.

Sardu C, Trotta MC, Sasso FC, Sacra C, Carpinella G, Mauro C, Minicucci F, Calabro P, et al. SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis. Cardiovasc Diabetol. 2023;22:80. https://doi.org/10.1186/s12933-023-01814-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sardu C, Massetti M, Testa N, Martino LD, Castellano G, Turriziani F, Sasso FC, Torella M, De Feo M, Santulli G, et al. Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up. Front Pharmacol. 2021;12:777083. https://doi.org/10.3389/fphar.2021.777083.

Article  CAS  PubMed  PubMed Central  Google Scholar 

James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, Andersen K, Austin D, Arefalk G, Carrick D, et al. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evid. 2024;3:EVIDoa2300286. https://doi.org/10.1056/EVIDoa2300286.

Article  PubMed  Google Scholar 

Harrington J, Udell JA, Jones WS, Anker SD, Bhatt DL, Petrie MC, Andersen KR, Sumin M, Zwiener I, Hernandez AF, Butler J. Baseline characteristics of patients enrolled in the EMPACT-MI trial. Eur J Heart Fail. 2023;25:1708–15. https://doi.org/10.1002/ejhf.2990.

Article  PubMed  Google Scholar 

Connelly KA, Zhang Y, Desjardins JF, Thai K, Gilbert RE. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. Cardiovasc Diabetol. 2018;17:99. https://doi.org/10.1186/s12933-018-0741-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kashiwagi Y, Nagoshi T, Yoshino T, Tanaka TD, Ito K, Harada T, Takahashi H, Ikegami M, Anzawa R, Yoshimura M. Expression of SGLT1 in Human Hearts and Impairment of Cardiac Glucose Uptake by Phlorizin during Ischemia-Reperfusion Injury in Mice. PLoS One. 2015;10:e0130605. https://doi.org/10.1371/journal.pone.0130605.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005;85:1093–129. https://doi.org/10.1152/physrev.00006.2004.

Article  CAS  PubMed  Google Scholar 

Ma S, Chen L, Yan J, Shen M, Zhang R, Li M, He M, Chen K, Zhu Y, Lin H, et al. Dapagliflozin attenuates residual cardiac remodeling after surgical ventricular reconstruction in mice with an enlarged heart after myocardial infarction. Biomed Pharmacother. 2022;156:113765. https://doi.org/10.1016/j.biopha.2022.113765.

Article  CAS  PubMed  Google Scholar 

Oshima H, Miki T, Kuno A, Mizuno M, Sato T, Tanno M, Yano T, Nakata K, Kimura Y, Abe K, et al. Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats. J Pharmacol Exp Ther. 2019;368:524–34. https://doi.org/10.1124/jpet.118.253666.

Article  CAS  PubMed  Google Scholar 

Lu Q, Liu J, Li X, Sun X, Zhang J, Ren D, Tong N, Li J. Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway. Mol Cell Endocrinol. 2020;501:110642. https://doi.org/10.1016/j.mce.2019.110642.

Article  CAS  PubMed  Google Scholar 

Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA, DeFronzo RA. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509–14. https://doi.org/10.1172/JCI70704.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ. Metabolic response to sodium-glucose cotransporter 2 inhib